China Delays Implementation Of Essential Drugs List; Analysts Say List Has Less Impact Than Earlier Predicted
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's Ministry Of Health announced it will delay implementation of the Essential Drug List in 30 percent of government-controlled clinics until the end of March
You may also be interested in...
Jiangbo Launches Generic Of Astrazeneca's Plendil, Targeting 153 Million Hypertension Patients In China
SHANGHAI - Nasdaq-listed Chinese pharma Jiangbo received approval from China's State FDA to manufacture Felodipine Sustained Release Tablets, a generic version of Plendil (felodipine)
Jiangbo Launches Generic Of Astrazeneca's Plendil, Targeting 153 Million Hypertension Patients In China
SHANGHAI - Nasdaq-listed Chinese pharma Jiangbo received approval from China's State FDA to manufacture Felodipine Sustained Release Tablets, a generic version of Plendil (felodipine)
China's New Guideline For Drug Pricing Favors Innovation And First-to-market Generics
SHANGHAI - The National Development and Reform Commission, China's powerful economic regulatory body, is collecting feedback from industry for a new drug pricing guideline, which details new rules for setting drug prices in China's changing healthcare system